Analysis of the clinicopathologic parameters showed that patients with high Ki-67 (≥30%) and high SPF (≥6.7%) had a significantly higher proportion of grade 3, ER-negative, and ≥stage pT2 cancers than the corresponding group with low and intermediate Ki-67 and low SPF. This evidence concerns the gene ESR1 and cancer.